The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the...

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Multiple myeloma (MM) is an incurable plasma cell malignancy.
• Drug resistance is a major challenge in MM treatment.
• The role of the activator protein-1 (AP-1) transcription factor family in MM is largely unknown.

Purpose of the Study:

• To investigate the role of AP-1 transcription factors in MM pathogenesis.
• To determine the specific function of JunB in MM cell proliferation, survival, and drug resistance.
• To evaluate JunB as a potential therapeutic target in MM.

Main Methods:

• Co-culture of MM cells with bone marrow stromal cells to assess JunB induction.
• JUNB gene knockdown using siRNA to evaluate its functional role.
• Murine MM model to assess tumor growth inhibition.
• Gene expression profiling to identify JunB-regulated pathways.
• Assessment of drug sensitivity in JunB-knockdown and JunB-activated MM cells.

Main Results:

• JunB was rapidly induced in MM cells co-cultured with bone marrow stromal cells.
• JUNB knockdown significantly inhibited MM cell proliferation and survival in vitro and reduced tumor growth in vivo.
• JunB regulates genes involved in apoptosis, DNA replication, and metabolism.
• JUNB knockdown restored dexamethasone sensitivity in resistant MM cells.
• JunB activation protected MM cells against dexamethasone- and bortezomib-induced cytotoxicity.

Conclusions:

• AP-1/JunB plays a critical role in MM cell proliferation, survival, and drug resistance.
• JunB is a promising therapeutic target for overcoming drug resistance in multiple myeloma.
• Targeting JunB may enhance the efficacy of existing MM therapies.